丁苯酞软胶囊与依达拉奉联合治疗脑梗死的疗效及安全性

Efficacy and safety of butylphthalide soft capsule combined with edaravone in the treatment of cerebral infarction

目的分析丁苯酞软胶囊联合依达拉奉治疗脑梗死(CI)的疗效及安全性。方法84例CI患者,根据随机数字表法分为观察组和对照组,各42例。对照组采取依达拉奉治疗,观察组实施丁苯酞软胶囊+依达拉奉治疗。对比两组不良反应发生情况及治疗前后的血脂、血液流变学以及炎症因子水平。结果观察组不良反应发生率为2.38%,与对照组的4.76%比较,差异无统计学意义(P>0.05)。治疗后,观察组总胆固醇(TC)(3.35±0.41)mmol/L、纤维蛋白原(FIB)(3.85±0.72)g/L、低密度脂蛋白胆固醇(LDL-C)(2.58±0.24)mmol/L、全血高切粘度(18.41±4.01)mPa·s、全血低切粘度(5.01±0.61)mPa·s、血浆粘度(1.77±0.33)mPa·s低于对照组的(4.90±0.36)mmol/L、(4.83±0.88)g/L、(3.44±0.36)mmol/L、(21.62±4.66)mPa·s、(5.57±0.78)mPa·s、(2.38±0.41)mPa·s;高密度脂蛋白胆固醇(HDL-C)(1.36±0.19)mmol/L高于对照组(1.02±0.13)mmol/L,差异具有统计学意义(P<0.05)。治疗后,观察组肿瘤坏死因子-α(TNF-α)(20.15±6.05)ng/L、白细胞介素-6(IL-6)(36.19±7.03)pg/ml低于对照组的(28.25±6.07)ng/L、(42.26±9.04)pg/ml,差异具有统计学意义(P<0.05)。结论CI患者通过实施依达拉奉与丁苯酞软胶囊联合治疗可有效改善其血脂水平,降低炎症因子水平,提升治疗效果,且安全性较高。

Objective To analyze the efficacy and safety of butylphthalide soft capsule combined with edaravone in the treatment of cerebral infarction(CI).Methods A total of 84 cases of CI patients were divided into observation group and control group according to the random numerical table,with 42 cases in each group.The control group was treated with edaravone,and the observation group was treated with butylphthalide soft capsules and edaravone.The occurrence of adverse reactions and blood lipids,hemorheology and inflammatory factors before and after treatment were compared between the two groups.Results The incidence of adverse reactions in the observation group was 2.38%,which was not statistically significant compared with 4.76%in the control group(P>0.05).After treatment,the total cholesterol(TC)(3.35±0.41)mmol/L,fibrinogen(FIB)(3.85±0.72)g/L,low-density lipoprotein cholesterol(LDL-C)(2.58±0.24)mmol/L,whole blood high shear viscosity(5.01±0.61)mPa·s,whole blood low shear viscosity(18.41±4.01)mPa·s and plasma viscosity(1.77±0.33)mPa·s in the observation group were lower than(4.90±0.36)mmol/L,(4.83±0.88)g/L,(3.44±0.36)mmol/L,(21.62±4.66)mPa·s,(5.57±0.78)mPa·s,(2.38±0.41)mPa·s in the control group;the high density lipoprotein cholesterol(HDL-C)(1.36±0.19)mmol/L in the observation group was higher than(1.02±0.13)mmol/L in the control group;all the differences were statistically significant(P<0.05).After treatment,the tumor necrosis factor-α(TNF-α)(20.15±6.05)ng/L and interleukin-6(IL-6)(36.19±7.03)pg/ml in the observation group were lower than(28.25±6.07)ng/L and(42.26±9.04)pg/ml in the control group,and the differences were statistically significant(P<0.05).Conclusion Edaravone combined with butylphthalide soft capsules can effectively improve the blood lipid levels of CI patients,reduce the levels of inflammatory factors,and improve the therapeutic effect,and has high safety.